The Medical Letter on Drugs and Therapeutics
A New Scorpion Antivenom
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Anascorp (Rare Disease Therapeutics), an intravenously administered antivenom derived from horse serum, has been approved by the FDA for treatment of clinical signs of scorpion envenomation.

SCORPION STINGS — About 17,000 scorpion stings are reported every year in the US.1 Arizona alone reports more than 10,000 annually. The bark scorpion (Centruroides sculpturatus) is the only scorpion in the US that can cause significant illness. Most stings result only in local pain and paresthesias, but severe symptoms including roving eye movements, loss of muscle control, slurred speech, drooling or frothing at the mouth, and respiratory distress can occur. Fatalities are rare. Serious envenomation, which usually occurs only in young children, is generally treated with a benzodiazepine such as midazolam and respiratory support, which may include intubation and ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: A New Scorpion Antivenom
Article code: 1393c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian